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ABSTRACT
Objectives: Erythropoietin (EPO), which is inversely
associated with blood haemoglobin (Hb), exerts
neuroprotective effects in experimental ischaemic
stroke (IS). However, clinical treatment trials have so
far been negative. Here, in patients with IS, we
analysed whether serum EPO is associated with (1)
initial stroke severity, (2) recovery and (3) functional
outcome.
Design: Prospective. Controls available at baseline.
Setting: A Swedish hospital-initiated study with
outpatient follow-up after 3 months.
Participants: Patients (n=600; 64% males, mean age
56 years, controls n=600) were included from the
Sahlgrenska Academy Study on IS (SAHLSIS).
Primary and secondary outcome measures: In
addition to EPO and Hb, initial stroke severity was
assessed by the Scandinavian Stroke Scale (SSS) and
compared with SSS after 3 months (follow-up) as a
measure of recovery. Functional outcome was
evaluated using the modified Rankin Scale (mRS) at
follow-up. Serum EPO and SSS were divided into
quintiles in the multivariate regression analyses.
Results: Serum EPO was 21% and 31% higher than
in controls at the acute phase of IS and follow-up,
respectively. In patients, acute serum EPO was 19.5%
higher in severe versus mild IS. The highest acute EPO
quintile adjusted for sex, age and Hb was associated
with worse stroke severity quintile (OR 1.70, 95% CI
1.00 to 2.87), better stroke recovery quintile (OR 1.93,
CI 1.09 to 3.41) and unfavourable mRS 3–6 (OR 2.59,
CI 1.15 to 5.80). However, the fourth quintile of EPO
increase (from acute to follow-up) was associated with
favourable mRS 0–2 (OR 3.42, CI 1.46 to 8.03). Only
the last association withstood full adjustment.
Conclusions: The crude associations between EPO
and worse stroke severity and outcome lost
significance after multivariate modelling. However, in
patients in whom EPO increased, the association with
favourable outcome remained after adjustment for
multiple covariates.
INTRODUCTION
Erythropoietin (EPO) is a peptide known to
promote brain plasticity.1 2 Circulating serum
EPO originates from the kidneys and it
increases net erythropoiesis by suppressing
erythroid precursor apoptosis in the bone
marrow to counteract anaemia.3 EPO and
EPO receptors are also expressed within the
brain, being upregulated in response to
ischaemic stroke (IS).4 Additionally, increases
in circulating EPO have been observed after
medial cerebral artery occlusion in patients.5
Furthermore, EPO has been shown to cross
the human blood-brain barrier (for review,
see ref. 1). With these ﬁndings in mind, EPO
administration was shown to have positive
effects in animal models of IS;2 for review
and meta-analysis.6 7 Surprisingly, although a
pilot study on 27 patients showed promising
results,5 following larger clinical trials on
intravenous EPO administration8 9 have
failed to show improvement in stroke
outcome. It has been proposed that the
negative results in later clinical studies could
have been due to an unfavourable inter-
action of tissue plasminogen activator and
EPO in patients receiving thrombolysis,10 as
compared with the earlier studies with much
fewer thrombolysed patients. Furthermore,
serum EPO is inversely related to anaemia or
low haemoglobin (Hb).3 Indeed, anaemia is
Strengths and limitations of this study
▪ A large study population including 600 patients
with ischaemic stroke (IS) with initial (acute) and
follow-up (3 months) evaluation.
▪ Six hundred population-based controls were
included at baseline.
▪ High participation rate and structured follow-up
in the Sahlgrenska Academy Study on IS
(SAHLSIS) study.
▪ Patients with IS were well characterised in terms
of multiple covariates, allowing multivariate
regression analyses to determine the indepen-
dency of associations.
▪ More early intraindividual sampling points and
the addition of cerebrospinal fluid samples could
have given more information regarding temporal
changes in, and origin of, erythropoietin levels.
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associated with worse outcome after IS.11 Therefore, it
would be important to consider effects of serum EPO
on IS in relation to Hb. Another factor that may be
important is whether the brain injury per se may induce
signiﬁcant amounts of local brain EPO expression. This
has been suggested by human4 and animal studies, pre-
dominantly via astrocyte hypoxia-induced factor
(HIF)-1α and more robustly HIF-2α.12 In these mice,
brain EPO expression and, to a lesser degree, circulating
EPO could be altered by genetic manipulation of HIF.
In humans, serum EPO levels peaked 2.6-fold at day 7
after medial cerebral artery occlusion, remaining ele-
vated until day 30 poststroke as analysed in a subsample
of nine placebo-treated patients.5 Altogether, this adds
rationale for a broader clinical investigation of both the
actual serum EPO levels and changes in EPO levels after
human IS. If endogenous serum EPO is independently
associated with better poststroke outcome, it would
support the need to revisit the timing and dosing of clin-
ical EPO administration.
Our primary hypothesis was that high acute serum
EPO levels, after correction for Hb, would promote
recovery and outcome after IS. Our secondary hypoth-
esis was that increasing serum EPO levels during the ﬁrst
3 months after stroke would also promote recovery and
improve outcome. We studied serum EPO in relation to
stroke severity, recovery and functional outcome in a
relatively large group of patients with IS from the
Sahlgrenska Academy Study on IS (SAHLSIS).13 14 In
the multivariate statistical analyses, adjustments were
made for Hb and C reactive protein (CRP), cardiovascu-
lar risk factors (diabetes, hypertension, smoking, body
mass index (BMI), dyslipidaemia), as well as age and
gender.
METHODS
Subjects and methods
The design of SAHLSIS has been reported previously13–
15 but is also compiled in more detail in online supple-
mentary information. Brieﬂy, a selection of 600 patients
(<70 years) with serum samples available with ﬁrst-ever
or recurrent acute IS and matched controls was
recruited consecutively at four stroke units in Western
Sweden between 1998 and 2003.
The original study was thus a case–control study esti-
mated to have reasonable power to detect genetic poly-
morphisms with respect to common stroke risk and
stroke subtypes.16 In the present study, case–control
comparison was not used other than for comparison
with baseline serum EPO. In the patient group, the
design was prospective with two longitudinal sampling
time points in the same cohort. Both in patients and
controls, CRP, EPO and Hb were analysed in blood
samples obtained between 0830 and 1030 before any
morning meal from overnight fasting participants. The
samples were drawn early poststroke (median 4 days),
designated ‘acute’ and after 3 months (median
101 days). Stroke severity at inclusion was scored using
the Scandinavian Stroke Scale (SSS), a scale similar to
the National Institutes of Health (NIH) stroke scale, but
with the highest score (58) for no clinical deﬁcit. To
facilitate statistical analysis and based on the skewed dis-
tribution of data, we divided the SSS scale into quintiles
(table 1). Assessment by SSS was repeated 3 months
poststroke and functional outcome was evaluated by the
modiﬁed Rankin Scale (mRS). Stroke recovery was
deﬁned as the change in SSS from acute stroke to
3-month poststroke (ΔSSS quintiles, table 1).
Anthropometric parameters (BMI) and data on hyper-
tension, diabetes mellitus, smoking and low-density lipo-
protein (LDL) levels were recorded (see online
supplementary information). Participants or next of kin
provided written informed consent.
Biochemical analysis
Serum EPO (mIU/mL) from controls (baseline only)
and from patients with IS during the acute phase and at
3-month follow-up was determined using the MSD
human hypoxia kit (K15122C, Meso Scale Discovery,
Rockville, Maryland, USA, see online supplementary
information). Hb and CRP were analysed at the
Department of Clinical Chemistry at the Hospital (see
online supplementary table S1).
Statistical evaluation
Statistical evaluation was performed using SPSS V.21
(SPSS Inc, Chicago, Illinois, USA). Regarding descriptive
data, independent or pairwise Student t tests were used
to compare the respective groups and χ2 tests were used
to evaluate differences in proportions. The change in
serum EPO from the acute phase to 3-month follow-up
was determined (ΔEPO). While Hb showed an approxi-
mately normal distribution, EPO was relatively skewed.
Therefore, EPO and ΔEPO levels were transformed into
quintiles (table 1). In ﬁgures 1A,B and 2A–C, differ-
ences in stroke severity, stroke recovery and functional
outcome with respect to quintiles of EPO were analysed
by analysis of variance (ANOVA) followed by Tukey’s
post hoc test for multiple comparisons. Crude correl-
ation analysis with unadjusted coefﬁcients (r) was
performed according to Pearson. Stroke severity (SSS
quintiles) and stroke recovery (ΔSSS quintiles) were
evaluated by ordinal logistic regression. Functional
outcome (unfavourable, mRS 3–6 vs favourable, mRS
0–2) was evaluated by binary logistic regression.
Regression yielded speciﬁc OR and 95% CIs for each
quintile of EPO as a factor. To evaluate the trend
(p trend), EPO quintiles were also analysed as a continu-
ous variable. Different models of adjustments are shown
with numbers (n) of complete records. Relatively few
participants had missing data,13 and possible bias was
not assessed with regard to missing data. Effects of bias
can, however, be deduced partly from the presentation
of included observations for each model. Sensitivity
analysis was not performed. Adjustments were also made
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for the cardiovascular risk factors (see introduction) as
well as for Hb and CRP. A two-tailed p value <0.05 was
considered statistically signiﬁcant.
RESULTS
Baseline data
Baseline demographics of controls and patients of
SAHLSIS have been reported previously13–15 and are
summarised in table 2. The traditional risk factors,
hypertension, diabetes and smoking, were more
common in patients, whereas LDL levels and BMI did
not differ. CRP levels were higher in patients than in
healthy controls. The fraction of anemic patients at base-
line was not different from that in healthy controls.
Table 2 also presents data on these factors according to
quintiles of initial stroke severity. Only the frequency of
diabetes and levels of CRP were signiﬁcantly higher in
severe versus mild IS.
Serum EPO and Hb levels
Serum EPO was 21% higher in patients in the acute
phase, and 31% higher after 3 months as compared with
healthy controls (table 2). Furthermore, the 3-month
serum EPO was 9% higher than the acute level
(p=0.025). Acute EPO did not correlate with the time
(days) of the ﬁrst blood draw (r=0.036, p=0.433, n=472)
and there was only a statistically non-signiﬁcant increase
of 5.7% from days 0–2 to 9–15 (see online supplemen-
tary ﬁgure S1). However, there was a correlation
between acute EPO and CRP (r=0.14, p=0.003, n=463), a
prognostic marker of infarct size.17 There were no
correlations between either acute or 3-month EPO and
age (data not shown).
Acute Hb levels were higher in patients (145±1.2 g/
dm3) than in controls (139±0.9 g/dm3, p<0.001). After
3 months, Hb levels (140±1.0 g/dm3) had decreased as
compared with the acute levels (p=0.001). There was no
correlation between acute Hb and time (days) of the
blood draw after IS onset (r=−0.01, p=0.8). Serum EPO
and Hb were negatively correlated (r=−0.219, p<0.001,
n=469). Anaemia is deﬁned as Hb <120 in females and
Hb <130 in males ((World Health Organization, WHO,
1997), and, as expected, acute EPO was higher in
anemic patients as compared with those with normal Hb
(13.6±3.0 vs 8.6±0.7 mIU/mL in males, and 17.5±7.6 vs
9.6±1.1 mIU/mL in females, both p≤0.001). However,
the anaemia was relatively mild with a mean Hb of 123
±2.5 g/dm3 in males and 107±6.7 g/dm3 in females.
Serum EPO and stroke severity and recovery
Serum EPO was 19.5% higher in severe IS as compared
with mild IS during the acute phase (table 2). We next
assessed associations between acute EPO levels, stroke
severity and 3-month stroke recovery (ΔSSS). Quintiles
of acute EPO correlated with worse initial stroke severity
(ﬁgure 1A), as well as a signiﬁcantly better stroke recov-
ery after 3 months (ﬁgure 1B). There was no signiﬁcant
correlation between acute EPO and 3-month SSS (r=
−0.056, p=0.235, n=448).
We performed ordinal logistic regressions with differ-
ent models to correct for Hb, cardiovascular covariates
and CRP (ﬁgure 1C–D). In the ordinal regressions
Table 1 Definitions of quintiles
Variable Unit New variable Name in text
SSS Units (0–58) SSS quintile SSS quintile
ΔSSS Units (3 months-acute) ΔSSS quintile Stroke recovery
EPO (acute) mIU/mL Acute EPO quintile Acute EPO quintile
EPO (3 months) mIU/mL 3-month EPO quintile 3-month EPO quintile
ΔEPO mIU/mL (3 months-acute) ΔEPO quintile ΔEPO quintile
Variable Information q1 q2 q3 q4 q5 Interpretation
SSS Ranges 1–36 37–50 51–54 55–57 58 Low values=severe
stroke
Severity Severe Major Moderate Minor Mild
n 117 126 120 109 128
ΔSSS Ranges −15 to −1 0 1–3 4–10 11–53 High values=more
recovery
n 15 148 114 146 123
EPO (acute) Ranges 1.20–5.399 5.4–6.799 6.8–8.499 8.5–11.339 11.34–78.1 High values=more EPO
n 95 94 103 102 98
EPO
(3-month)
Ranges 1.6–6.099 6.1–7.699 7.7–9.599 9.6–12.699 12.7–57 High values=more EPO
n 88 91 101 95 94
ΔEPO Ranges −71 to −1.60 −1.60 to 0.30 0.30–1.80 1.80–3.80 3.80–31.1 High values=increase of
EPO
n 87 91 92 87 92
EPO, erythropoietin; SSS, Scandinavian Stroke Scale.
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adjusted for sex and age, the association of acute EPO
with worse stroke severity was conﬁrmed (OR 1.97, CI
1.19 to 3.26 for the ﬁfth quintile, ﬁgure 1C). However,
adjustments for Hb, cardiovascular confounders and
CRP weakened the associations and statistical signiﬁ-
cance was lost.
With regard to 3-month recovery (ΔSSS, ﬁgure 1D),
participants in the highest quintile of acute EPO had a
twofold greater chance (OR 2.08, CI 1.20 to 3.58) of
having a better recovery 3 months after stroke than
those in the lowest quintile. Again, associations wea-
kened and statistical signiﬁcance was lost after adjust-
ments for multiple covariates (ﬁgure 1D).
Serum EPO and 3-month functional outcome
Next, we assessed whether serum EPO was associated
with functional outcome indexed as unfavourable (mRS
3–6) and favourable (mRS 0–2). As could be expected,
higher quintiles of acute EPO were associated with
worse functional outcome of stroke (ﬁgure 2A).
Figure 1 Stroke severity and recovery according to quintiles (q1–q5) of serum EPO during the acute phase. (A) Initial stroke
severity according to the SSS units. (B) Stroke recovery (ΔSSS) after 3 months (q1 indicating deterioration and q5 improvement).
(C) ORs and 95% CIs for the associations (ordinal logistic regression) between acute EPO quintiles and initial stroke severity, as
measured by SSS quintiles. (D) As in panel C, but for stroke recovery (ΔSSS quintiles). For (A–D), numbers of included patients
are shown above each quintile (q1–q5). Statistically significant differences between groups (as evaluated by ANOVA followed by
Tukey’s post hoc test) are shown with brackets. In A and B, the boxes show the overall correlation coefficients according to
Pearson including p values. In C and D, the boxes show the overall association using acute EPO quintiles as a continuous
variable (p trends). Different models of adjustment in which sex (S), age (A), cardiovascular factors (C) and CRP are included as
indicated. ANOVA, analysis of variance; CRP, C reactive protein; EPO, erythropoietin; Hb, haemoglobin; SSS, Scandinavian
Stroke Scale.
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Quintiles of EPO at 3 months, on the other hand, did
not show any signiﬁcant association with outcome
(ﬁgure 2B). Furthermore, analyses of the change in
serum EPO from the acute phase to 3-month follow-up
(ΔEPO quintiles) demonstrated that in participants with
increases in EPO, there were signiﬁcantly more patients
with better outcome (ﬁgure 2C).
Multivariate binary logistic regression analyses were
next performed to evaluate the inﬂuence of serum EPO
on unfavourable versus favourable mRS scores. Since
serum EPO did not change signiﬁcantly between
different days of blood sampling in the acute phase, this
factor was not added into the models. Participants in the
highest acute EPO quintile showed a 2.5-fold higher risk
of having an unfavourable functional outcome after
3 months (OR 2.59, CI 1.18 to 5.68, ﬁgure 2D). This was
independent of Hb and cardiovascular risk factors but
not of CRP. Furthermore, participants in the higher
quintiles of ΔEPO (indicating increased EPO overtime)
were more likely to have a better/favourable functional
outcome (ﬁgure 2E). The associations remained in all
models, including the addition of CRP. Of note is that
Figure 2 Functional outcome after stroke as indexed by the modified Rankin Scale (mRS) and regressions of favourable mRS
according to quintiles (q1–q5) of acute serum erythropoietin (EPO), 3-month serum EPO and changes in EPO (ΔEPO). (A)
Functional outcome (mRS units) according to acute EPO quintiles. (B) Functional outcome (mRS units) according to 3-month
EPO quintiles. (C) Functional outcome (mRS units) according to ΔEPO quintiles. (D) ORs and 95% CIs for the associations
(binary logistic regression) of mRS (values 3–6) over favourable (mRS 0–2) functional recovery according to quintiles of acute
EPO. (E) Same as in D but mRS 0–2 over mRS 3–6 according to ΔEPO quintiles. Numbers of included patients are shown
above each quintile (q1–q5). No statistically significant differences were found between groups as evaluated by analysis of
variance. In A–C, the boxes show the overall correlation coefficients according to Pearson and the corresponding p values. In D
and E, the boxes show the overall association using acute EPO quintiles as a continuous variable (p trends). Different models of
adjustment with abbreviations as in ‘C’.
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Table 2 Baseline characteristics of SAHLSIS participants and healthy controls
All patients (P) Healthy controls (C) P vs C
Variable Mean±CI n Mean±CI n p
Total number (% of all, n) 100 600 100 600
Females (n) 215 215
Males (n) 385 385
Males (fraction of all) 0.64 0.64 >0.15
Age (years) 56.7 (55.9 to 57.5) 600 56.8 (56 to 57.6) 600 >0.15
BMI (kg/m2)* 26.5 (26.1 to 26.9) 585 26.5 (26.2 to 26.8) 599 >0.15
Hypertension (fraction)* 0.6 592 0.37 599 <0.001
Diabetes (fraction)* 0.19 600 0.06 598 <0.001
Smoking (fraction)* 0.39 597 0.18 600 <0.001
Dyslipidaemia (LDL level)* 3.3 (3.2 to 3.4) 506 3.3 (3.2 to 3.4) 597 >0.15
CRP (mg/L) 12.2 (10.3 to 14.1) 563 5.9 (5.7 to 6.1) 589 <0.001
EPO (acute) 9.3 (8.7 to 9.9) 492 7.7 (7.4 to 8.0) 513 <0.001
EPO (3 months) 10.1 (9.6 to 10.6) 469 See acute values >0.15
Anaemia (fraction) 0.072 41 0.079 47 >0.15
SSS (acutely) 47.1 (46 to 47.2) 600 NA
SSS (3 months) 54.3 (53.7 to 55) 546 NA
mRS (3 months) 1.9 (1.8 to 2) 568 NA
Patients according to quintiles of severity of SSS score
Severe (1–36, A) Major (37–50, B) Moderate (51–54, C) Minor (55–57, D) Mild (58, E) A vs E
Variable Mean±CI n Mean±CI n Mean±CI n Mean±CI n Mean±CI n p Value
Total number
(% of all, n)
19.5 117 21.0 126 20.0 120 18.2 109 21.3 128 NA
Females (n) 41 45 42 43 44 NA
Males (n) 76 81 78 66 84 NA
Males (fraction
of all)
0.65 0.64 0.65 0.61 0.66 >0.15
Age (years) 55.9 (54.0 to 57.8) 117 59.3 (57.8 to 60.8) 126 56.1 (54.1 to 58.1) 120 56.6 (54.9 to 58.3) 109 55.4 (53.4 to 57.4) 128 >0.15
BMI (kg/m2)* 26.0 (25.1 to 26.9) 111 26.9 (26.1 to 27.7) 122 27.2 (26.4 to 28.0) 119 26.5 (25.7 to 27.3) 107 26.1 (25.3 to 26.9) 126 >0.15
Hypertension
(fraction)*
0.54 111 0.65 125 0.64 119 0.64 109 0.52 128 >0.15
Diabetes (fraction)* 0.2 117 0.25 126 0.21 120 0.16 109 0.14 128 0.025
Smoking (fraction)* 0.41 114 0.41 126 0.32 120 0.43 109 0.38 128 >0.15
Dyslipidaemia (LDL
level)*
3.1 (2.9 to 3.3) 92 3.3 (3.1 to 3.5) 103 3.4 (3.2 to 3.6) 100 3.4 (3.2 to 3.6) 96 3.4 (3.2 to 3.6) 115 0.11
CRP (mg/L) 17.6 (12.3 to 22.9) 105 12.0 (7.9 to 16.1) 119 12.2 (7.1 to 17.2) 114 9.2 (5.0 to 13.4) 103 10.3 (7.3 to 13.3) 122 0.02
EPO (acute) 10.6 (9.4 to 11.8) 93 9.6 (7.9 to 11.3) 106 8.4 (7.7 to 9.1) 105 9.4 (7.6 to 11.2) 87 8.8 (7.6 to 10.0) 101 0.043
EPO (3 months) 9.9 (8.8 to 11.0) 81 9.5 (8.6 to 10.4) 104 10.5 (9.4 to 11.6) 103 11.0 (9.5 to 12.5) 81 10.0 (8.5 to 11.5) 100 >0.15
Continued
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quintile 4 of ΔEPO (model with full adjustment OR
2.98, CI 1.21 to 7.36) showed the largest association with
favourable outcome. Although the values of acute EPO
varied relatively little with respect to the day of sampling
(see online supplementary ﬁgure S1), day of sampling
could nevertheless affect the magnitudes of associations
with respect to ΔEPO. We therefore performed an ana-
lysis using the acute samples of EPO obtained days 3–5
after IS (n=195). Statistical signiﬁcance was maintained
at a somewhat lower level, but the ORs were somewhat
greater (see online supplementary information, results,
text), supporting that the association of ΔEPO with
favourable outcome was not largely obscured by the day
on which the acute sample was taken.
DISCUSSION
Principal findings
This is the ﬁrst large study to investigate serum EPO cor-
rected for Hb levels in relation to human IS. After
3 months, serum EPO was higher than at the acute time
point and also higher in patients than in healthy con-
trols, indicating that EPO increased. However, in com-
parison to a previous smaller study,5 in which serum
EPO increased 2–3 fold with a peak at 7 days after IS,
our ﬁndings indicate much smaller increases. Although
there was a crude association between acute EPO and
worse stroke severity and worse functional outcome, in
the multivariate models, these associations weakened
and lost statistical signiﬁcance. Furthermore, 3-month
EPO levels did not associate with functional outcome. In
contrast, an increase in EPO levels between the two time
points (ΔEPO) was associated with better functional
outcome in all models.
Strengths and limitations
Although there is a methodological strength of this
study including consecutive recruitment of well-
characterised IS participants, the age of the study group
is relatively young IS cases (mean age 56 years). Thus,
the associations found may be different in a population
of older IS participants which more often exhibits
anaemia of various causes. Since the hospitalisation rate
is high (84–95%) for strokes in Sweden,18 selection bias
is unlikely. Also, the study includes detailed information
on cardiovascular confounders, as well as CRP, an infarc-
tion size marker,17 and Hb levels, which is crucial to the
interpretation of EPO levels.3 Although there was a good
record of most parameters, there were data missing for
some patients (table 2), especially with regard to dyslipi-
daemia (LDL levels). Overlap of missing data generated
approximately 20–25% missing observations in the ﬁnal
models of multivariate analysis. However, we believe that
the speciﬁc bias of these missing values is minimal, espe-
cially in the light of the fact that LDL levels differed very
little across the severities of IS. The study includes meas-
urement of within-participant change (acute phase and
after 3 months), which is in contrast to many studies
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having sampling points within the ﬁrst week after IS
only, and few patients were lost to follow-up. Weaknesses
include the relatively small sample size and lack of repli-
cation in another geographic area. Furthermore, regres-
sion analysis is a poor method to assess causality. More
sampling points and predisease samples would have
been helpful to address causal relationships. Although
our study indicates relatively small acute changes in
serum EPO, the previous study by Ehrenreich et al5
showed larger increases. It would therefore have been
preferable to have consecutive intraindividual sampling
in the acute phase, in order to deﬁnitely establish how
endogenous serum EPO is regulated. Finally, although
EPO is able to cross the blood-brain barrier,1 5 the pro-
portion of EPO that actually does so is unknown. To
address that issue, cerebrospinal ﬂuid (CSF) sampling
would have been preferable.
Why is there only a positive effect on outcome via
increasing levels of EPO?
Acute serum EPO is associated with worse stroke severity.
While acute EPO did not associate with time of blood
draw (days after stroke onset), the crude association with
CRP levels indicates that EPO levels may be inﬂuenced
by the size of the infarct (or vice versa). The association
between EPO and worse stroke severity may also reﬂect
the fact that serum EPO is mainly a direct indicator of
previous anaemia, which is a known negative factor for
stroke severity and recovery.11 19 This is indeed what we
observed for initial stroke severity (SSS) and stroke
recovery (ΔSSS) with regard to initial acute EPO, where
statistical signiﬁcance was decreased (but not lost) when
adding Hb into the models. With full adjustment for car-
diovascular covariates and CRP, statistical signiﬁcance
was, however, lost. In contrast, with regard to changes in
EPO (ΔEPO), statistical signiﬁcance remained in all
models. Therefore, the associations between increases in
serum EPO and favourable outcome are only partly
explained by effects of Hb/anaemia. There are other
possible bystander effects, that is, the possibility of local
brain upregulation of EPO4 5 12 in larger infarctions.
Also, vigorous physical activity has been shown to
increase serum EPO.20 Our results do not allow us to dis-
criminate between these two possibilities.
Further on, acute serum EPO was associated with
better recovery 3 months after stroke, independent of
low Hb but not of cardiovascular confounders or CRP
(ﬁgure 1B). To some degree, this probably reﬂects a
regression towards the mean, that is, those with greater
initial injuries have a greater recovery in terms of
improved SSS units. Altogether, our data reject the idea
that the actual EPO levels will have a net beneﬁcial
effect on early recovery and functional independence
3 months poststroke. This would be in line with the
results of a phase II/III clinical study which failed to
show positive effects of intravenously given EPO within
48 h after stroke onset.8 However, it should be pointed
out that the concentrations of EPO achieved in a pilot
study with similar design were much higher (∼250-fold)
than the endogenous circulating EPO,5 which hampers
comparison to our results. In addition, apart from the
different concentrations of EPO in the mentioned clin-
ical trial and our study, the negative results8 were largely
associated with increased secondary haemorrhagic trans-
formations, possibly via interactions between EPO and
tissue plasminogen activator.10 In our study, haemor-
rhagic transformations were not recorded, but they are
usually of low frequency in cohorts not being thrombo-
lysed (thrombolysed patients were only n=5 in our
study).
Interestingly, 3-month serum EPO levels were neutral
with respect to association with functional outcome,
while increasing EPO levels between the two time points
were associated with favourable outcome. The last associ-
ation ﬁrmly withstood confounder adjustments of Hb,
cardiovascular factors and CRP. Therefore, it appears
that changes (increases) in serum EPO are associated
with better stroke outcome, which in turn preserves the
idea that EPO has a positive role in human IS recovery.
It might even be the case that the increase in serum
EPO may derive from the local upregulation of brain
EPO that has been reported after stroke injuries in aut-
opsies 4 and in animal experiments on hypoxia 12. This
suggests that individuals having a higher potential of
upregulating local brain EPO, which may be reﬂected in
elevated serum EPO, exhibit better recovery and
outcome. As above, additional sampling points including
analysis of CSF could elucidate this more clearly.
Implications and unanswered questions
In a well-characterised study population consisting of
600 patients with IS and 600 controls, we have shown
that unadjusted serum EPO in the acute phase of IS is
associated with worse stroke severity as well as with
better recovery using the SSS scale. Furthermore, the
increase in serum EPO (ΔEPO) from the acute phase to
the 3-month follow-up was associated with favourable
outcome using the mRS instrument, and the latter asso-
ciation was the only one that withstood full adjustment
(Hb, cardiovascular confounders and CRP) in the mul-
tiple regression analyses. Therefore, our results suggest
that an increasing level of EPO is a predictor of positive
functional outcome after IS, although the associations
between serum EPO and IS are complicated and to a
large degree dependent on coexisting morbidities.
Speciﬁcally, our study indicates that rather small
increases in EPO concentration (fourth quintile of
ΔEPO was deﬁned as 1.9–3.8 mIU/mL, which corre-
sponds to a relative increase of approximately 20–40% as
compared with the mean acute serum EPO), in contrast
to larger changes (ﬁfth quintile), are associated with
optimal outcome. In terms of the SSS scale, the differ-
ences in SSS units between acute EPO quintiles were
relatively small and the associations between acute EPO
quintiles and SSS measures were of moderate strength
(ORs ≤2; ﬁgure 1). Furthermore, the associations
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between acute EPO quintiles and SSS measures lost stat-
istical signiﬁcance when adding covariates into the
models, and therefore the importance of these ﬁndings
is unclear. Our study has not investigated early intraindi-
vidual (<2 to 3 weeks) temporal changes in serum EPO
in relation to infarction size, giving room for further
studies with more sampling points. Finally, there is also a
need for studies measuring CSF EPO levels to determine
whether changes in EPO are primarily originating from
the brain or kidneys.
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